INmune Bio (NASDAQ:INMB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of INmune Bio (NASDAQ:INMB) from a sell rating to a hold rating in a report released on Sunday morning.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of INmune Bio in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $18.00.

INmune Bio Trading Down 4.4%

INmune Bio stock opened at $1.51 on Friday. INmune Bio has a 52 week low of $1.50 and a 52 week high of $11.64. The stock has a market cap of $40.14 million, a price-to-earnings ratio of -0.71 and a beta of 0.95. The company’s 50-day moving average price is $1.89 and its two-hundred day moving average price is $3.81.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings data on Thursday, October 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.07. Research analysts expect that INmune Bio will post -2.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On INmune Bio

A number of institutional investors and hedge funds have recently modified their holdings of INMB. Rhumbline Advisers grew its holdings in shares of INmune Bio by 14.4% in the 1st quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock worth $150,000 after acquiring an additional 2,409 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of INmune Bio by 9.0% in the 1st quarter. Bank of New York Mellon Corp now owns 54,923 shares of the company’s stock valued at $429,000 after purchasing an additional 4,521 shares during the period. MAI Capital Management boosted its position in shares of INmune Bio by 6.0% in the 1st quarter. MAI Capital Management now owns 106,797 shares of the company’s stock valued at $834,000 after purchasing an additional 6,030 shares during the period. Quarry LP purchased a new position in INmune Bio in the 1st quarter worth about $48,000. Finally, Charles Schwab Investment Management Inc. increased its stake in INmune Bio by 19.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 41,320 shares of the company’s stock worth $323,000 after purchasing an additional 6,654 shares in the last quarter. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.